NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2009.60 5.20 (0.26%)

216.3K NSE+BSE Volume

NSE 23 Sep, 2025 1:15 PM (IST)

91,789.4

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Lupin's Pune biotech facility receives Form 483 with four observations from the US FDA See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

29 Oct 2021

2009.60

0.26%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

12 Aug 2021

2009.60

0.26%

Q1FY22 Result Update - Miss on all counts; Competitive pressure and lack of visibility drives downgrade - REDUCE

Sell: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Tax rate guided at 27-28% from 30% in FY22E. We see a near term challenging period for Lupin (LPC) and downgrade our recommendation to REDUCE' from Accumulate' due to delay in resolution of two key plants (Goa and Indore unit-2) as more than 50% of pending ANDAs...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

12 Aug 2021

2009.60

0.26%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

18 May 2021

2009.60

0.26%

LUPIN LIMITED

Hold: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

17 May 2021

2009.60

0.26%

Pick of the Week:17 MAY 2021

Buy: Lupin Ltd.

Axis Direct

We recommend a BUY on the stock with a target price of Rs 1,400/share.

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

15 May 2021

2009.60

0.26%

HSIE Results Daily: Lupin, Tata Power, Mphasis, Voltas, BSE, Sagar Cements

Accumulate: Lupin Ltd.

HDFC Securities

Voltas: Voltas continued to surprise both on revenue and margin front, beating our as well as street's expectation. UCP revenue/EBIT grew by 20/28% YoY (HSIE 25/20%) despite firm base (4QFY20 revenue/EBIT growth of 20/69%). UCP volume growth was at 18% YoY and YTD market share was at 25.6% (24.2% last year). Market share gain, pre-buying, increased mobility, and anticipation of strong demand in season supported the 4Q growth. UCP revenue/EBIT growth in FY21 was at -13/-2% YoY despite a firm base (29/57% in FY20) and summer 2020 being a washout. . We were expecting supply constraints and RM inflation to impact EBIT margin by (60bps) in 4Q but Voltas surprised with 100bps EBIT margin expansion to 15.6% (12 quarters highest margin). EMPS revenue was up by strong 37% YoY (-18% in 4QFY20) and 9% QoQ, HSIE 25%. EMPS EBIT margin also improved sharply by 700bps to 8.4% (10 quarters highest margin), HSIE 3.5%. COVID-led lockdown again reduced selling window for RAC (impact is unlike last year). We cut our EPS estimates for FY22 by 7% while maintain for FY23. We value Voltas on SoTP basis, (UCP/EPMS/EPS P/E at 45/15/15x and Volt-Beko P/S of 4x) on Jun-23 (earlier Mar-23) to derive a target price of INR 1,100 arriving at an implied P/E of 37x. Maintain ADD. BSE: BSE delivered the best quarterly performance over the past four years with revenue growth of 26% QoQ and a margin of 30.3% (multi-quarter high). Growth was driven by market-linked revenue, with core transaction/book building increasing by 46.7/81.2% QoQ. BSE gained...

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

14 May 2021

2009.60

0.26%

Lupin Ltd

Hold: Lupin Ltd.

Recommendation Target

ICICI Securities Limited

Q4FY21 operational performance was in-line with I-direct estimates whereas profitability was above expectations due to higher other income and a lower tax outgo. As per the management, FY22 US sales would be largely driven by gProAir ramp-up and new launches such as Brovana. Domestic branded formulations are expected to grow in double digits in FY22. The resolution of warning letter and clearance of official action indicated (OAIs) status on plants could be the near term lever along with progress on margins front. However, like other pharma majors, Lupin has also chalked out a product,...

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

14 May 2021

2009.60

0.26%

Medium term triggers adequately priced

Neutral: Lupin Ltd.

Recommendation Target

Motilal Oswal

LPC's 4QFY21 operational performance was slightly below our estimates, led by a weak Flu season in the US and YoY decline in API sales. In addition to the ongoing exercise to control opex, it remains on track for the review process of limited competition products for developed markets. We have raised our FY22E/FY23E EPS by 2%/9% to factor in: a) outperformance in the domestic formulation (DF) segment, b) niche launches in the US and European market, c) extended benefit of cost savings in DF, and d) lower effective tax rate. We value LPC at 25x 12-month forward...